Comeaux Evan Q, Cuya Selma M, Kojima Kyoko, Jafari Nauzanene, Wanzeck Keith C, Mobley James A, Bjornsti Mary-Ann, van Waardenburg Robert C A M
From the Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, Alabama 35294.
the University of Alabama at Birmingham Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama 35294.
J Biol Chem. 2015 Mar 6;290(10):6203-14. doi: 10.1074/jbc.M114.635284. Epub 2015 Jan 21.
Tyrosyl-DNA phosphodiesterase I (Tdp1) catalyzes the repair of 3'-DNA adducts, such as the 3'-phosphotyrosyl linkage of DNA topoisomerase I to DNA. Tdp1 contains two conserved catalytic histidines: a nucleophilic His (His(nuc)) that attacks DNA adducts to form a covalent 3'-phosphohistidyl intermediate and a general acid/base His (His(gab)), which resolves the Tdp1-DNA linkage. A His(nuc) to Ala mutant protein is reportedly inactive, whereas the autosomal recessive neurodegenerative disease SCAN1 has been attributed to the enhanced stability of the Tdp1-DNA intermediate induced by mutation of His(gab) to Arg. However, here we report that expression of the yeast His(nuc)Ala (H182A) mutant actually induced topoisomerase I-dependent cytotoxicity and further enhanced the cytotoxicity of Tdp1 His(gab) mutants, including H432N and the SCAN1-related H432R. Moreover, the His(nuc)Ala mutant was catalytically active in vitro, albeit at levels 85-fold less than that observed with wild type Tdp1. In contrast, the His(nuc)Phe mutant was catalytically inactive and suppressed His(gab) mutant-induced toxicity. These data suggest that the activity of another nucleophile when His(nuc) is replaced with residues containing a small side chain (Ala, Asn, and Gln), but not with a bulky side chain. Indeed, genetic, biochemical, and mass spectrometry analyses show that a highly conserved His, immediately N-terminal to His(nuc), can act as a nucleophile to catalyze the formation of a covalent Tdp1-DNA intermediate. These findings suggest that the flexibility of Tdp1 active site residues may impair the resolution of mutant Tdp1 covalent phosphohistidyl intermediates and provide the rationale for developing chemotherapeutics that stabilize the covalent Tdp1-DNA intermediate.
酪氨酰 - DNA磷酸二酯酶I(Tdp1)催化3'-DNA加合物的修复,例如DNA拓扑异构酶I与DNA之间的3'-磷酸酪氨酰连接。Tdp1含有两个保守的催化组氨酸:一个亲核组氨酸(His(nuc)),它攻击DNA加合物以形成共价3'-磷酸组氨酰中间体;以及一个广义酸碱组氨酸(His(gab)),它分解Tdp1 - DNA连接。据报道,His(nuc)突变为丙氨酸的突变蛋白无活性,而常染色体隐性神经退行性疾病SCAN1被认为是由于His(gab)突变为精氨酸导致Tdp1 - DNA中间体稳定性增强所致。然而,我们在此报告,酵母His(nuc)丙氨酸(H182A)突变体的表达实际上诱导了拓扑异构酶I依赖性细胞毒性,并进一步增强了Tdp1 His(gab)突变体的细胞毒性,包括H432N和与SCAN1相关的H432R。此外,His(nuc)丙氨酸突变体在体外具有催化活性,但活性水平比野生型Tdp1低85倍。相比之下,His(nuc)苯丙氨酸突变体无催化活性,并抑制His(gab)突变体诱导的毒性。这些数据表明,当His(nuc)被含有小侧链(丙氨酸、天冬酰胺和谷氨酰胺)的残基取代时,另一个亲核试剂具有活性,但被含有大侧链的残基取代时则无活性。实际上,遗传、生化和质谱分析表明,紧邻His(nuc) N端的一个高度保守的组氨酸可以作为亲核试剂催化共价Tdp1 - DNA中间体的形成。这些发现表明,Tdp1活性位点残基的灵活性可能会损害突变型Tdp1共价磷酸组氨酰中间体的分解,并为开发稳定共价Tdp1 - DNA中间体的化疗药物提供了理论依据。